News

Back to the list
abivaxlogo.jpeg
BioMedTech Press Release

Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting

miR-AGE study has been approved by French and German regulators, and most recently by the British and Italian regulatory authorities

Download PDF
Brazilian Health Regulatory Agency approves Phase 2b/3 study miR-AGE of ABX464 in COVID-19 patients
miR-AGE study has been approved by French and German regulators, and most recently by the British and Italian regulatory authorities
French government announced the selection of six COVID-19 projects to finance with a total of 78m EUR, with Abivax to receive 36m EUR
Final agreements for the 36m EUR funding have been signed with Bpifrance
Patient enrollment in ulcerative colitis Phase 2b trial post COVID-19 getting back on track, with 113 of 232 randomized to date
All resolutions presented during the general meeting were adopted

Also to be discovered